Argatroban anticoagulation in renal dysfunction: A literature analysis

Nephron - Clinical Practice

Volumn 109, Issue 2, 2008, Pages

  Hursting, Marcie J ^a   Murray, Patrick T ^b  

^a Clinical Science Consulting   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antithrombin deficiency; Argatroban; Dialysis; Heparin induced thrombocytopenia; Renal dysfunction; Renal replacement therapy

Indexed keywords

ARGATROBAN; HEPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ANTICOAGULANTS; COMORBIDITY; HUMANS; KIDNEY FAILURE; PIPECOLIC ACIDS; PREVALENCE; THROMBOSIS; TREATMENT OUTCOME;

EID: 48249127952     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139993     Document Type: Article

References (62)

1. Hara T, Naito K: Inherited antithrombin deficiency and end stage renal disease. Med Sci Monit 2005;11:RA346-RA354.
2. Martel N, Lee J, Wells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106:2710-2715.
3. Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361-369.
4. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004;126:311S-337S.
5. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329.
6. Argatroban Injection Prescribing Information: GlaxoSmithKline, Research Triangle Park, July 2005.
7. Izawa O, Katsuki M, Komatsu T, Iida S: Pharmacokinetics studies of argatroban (MD805) in human - concentrations of argatroban and its metabolites in plasma, urine, and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986;14(suppl 5):251-263.
8. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang I-K, Rifkin SD, Moran J, Hursting MJ, Kelton JG: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
9. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 2003;163:1849-1856.
10. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T: Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996;28:82-85.
11. Murray PT, Hursting MJ: Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Renal Failure 2006;28:537-539.
12. Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P: Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006;104:c143-c148.
13. Fischer K-G: Hirudin in renal insufficiency. Semin Thromb Hemost 2002;28:467-482.
14. O'Shea SI, Ortel TL, Kovalik EC: Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003;16:61-67.
15. McIntosh BA: Developing an algorithm for treating heparin-induced thrombocytopenia. Clin Adv Hematol Oncol 2002;2:216-222.
16. Matsuo T, Yamada T, Yamanashi Y, Kodama K: Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis. Clin Lab Haematol 1989;11:213-219.
17. Matsuo T, Yamada T, Matsuo M, Sakai R: Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis. Biomater Artif Cells Immobilization Biotechnol 1991;19:185-191.
18. Kubiak DW, Szumita PM, Fanikos JR: Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1119-1123.
19. Spinler SA, Dager W: Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1955-1956.
20. Mejak B, Giacomuzzi C, Hefler E, You X, Underleider R, Shen I, Boshkov L: Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 2004;36:178-181.
21. Hursting MJ, Dubb J, Verme-Gibboney CN: Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006;28:4-10.
22. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005;39:1601-1605.
23. Ota K, Kawaguchi H, Nakagawa S, Koshikawa S, Maeda K, Matsui N, Hirasawa Y, Sasaoka T: Clinical evaluation of a new thrombin inhibitor available for haemodialysis. Proc Eur Dial Transplant Assoc 1983;20:144-149.
24. Matsuo T, Nakao K, Yamada T, Matsuo O: Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 1986;41:33-41.
25. Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O: Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988;52:165-171.
26. Kario K, Matsuo T, Yamada T, Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275-279.
27. Ohteki H, Furukawa K, Ohnishi H, Narita Y, Sakai M, Doi K: Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000;48:39-46.
28. Akashi K, Masui Y, Soma K, Kawada T, Takahoshi Y, Yamanaka I, Inokuchi S, Sugiyama M: Clinical trial of argatroban, a direct thrombin inhibitor, as an anticoagulant in cardiopulmonary support and apheresis in emergency patients: a preliminary report. J Artif Organs 2002;5:223-227.
29. Arpino PA, Hallisey RK: Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38:25-29.
30. Murray PM, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK: A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004;66:2446-2453.
31. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT: Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005;39:231-236.
32. Koster A, Hentschel T, Groman T, Kuppe H, Hetzer R, Harder S, Fischer K-G: Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007;133:1376-1377.
33. Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N: Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003;18:1623-1630.
34. Guzzi LM, McCollum DA, Hursting MJ: Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006;22:169-176.
35. Levine RL, Hursting MJ, McCollum D: Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006;129:1167-1175.
36. Matsuo T, Nakao K, Yamada T, Matsuo O: A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. Thromb Res 1986;44:247-251.
37. Matsuo T, Yamada T, Yamanashi T, Ryo R: Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res 1990;58:663-666.
38. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992;82:627-629.
39. Koide M, Yamamato S, Matsuo M, Suzuki S, Arima N, Matsuo T: Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995;10:2137-2140.
40. Lewis BE, Grassman ED, Wrona L, Rangel Y: Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:54-58.
41. Dager WE, White RH: Argatroban for heparin-induced thrombocytopenia in hepatorenal failure and CVVHD. Ann Pharmacother 2003;37:1232-1236.
42. De Denus S, Spinler SA: Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003;37:1237-1240.
43. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY: Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-654.
44. Tokuda Y, Matsumoto M, Sugita T, Nishizawa J, Matsuyama K, Yoshida K, Matsuo T: Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ J 2003;67:889-890.
45. Edwards JT, Hamby JK, Worrall NK: Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75:1622-1624.
46. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G: Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-414.
47. Hara T, Jojima K, Takeuchi K, Takai K, Naito K: Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis. Thromb Haemost 2004;92:208-210.
48. Hallman SE, Hebbar L, Robison J, Uber WE: The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia. Anesth Analg 2005;100:946-948.
49. Scott LK, Grier LR, Conrad SA: Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban. Pediatr Crit Care Med 2006;7:473-475.
50. Zangan SM, Van Ha TG, Funaki B: Systemic anticoagulation with argatroban during arteriovenous dialysis graft thrombolysis. J Vasc Interv Radiol 2006;17:1717-1718.
51. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184.
52. Jang IK, Lewis BE, Matthai WH, Kleiman NS: Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label nonrandomized pilot study. J Thromb Thrombolysis 2004;18:31-37.
53. Dreisbach AW, Lertora JJ: The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003;16:45-50.
54. Krieger D, Geisen U, Is A, Fischer KG: Hemodialyser membranes allow for removal of argatroban. J Thromb Haemost 2007;5(suppl 1):P-S-669.
55. Smythe M, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 2005;11:371-374.
56. Kiser TH, Jung R, MacLaren R, Fish DN: Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736-1745.
57. Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L: Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21:86-92.
58. Rice L, Hursting MH, Baillie GM, McCollum DA: Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007;47:1028-1034.
59. Novastan® Injection (Argatroban Preparation) Prescribing Information: Mitsubishi Chemical Corp, Tokyo, March 1998.
60. Malherbe S, Tsui B, Stobart K, Koller J: Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004;100:443-445.
61. Alsoufi B, Boshkov LK, Kirby A, Ibsen L, Dower N, Shen I, Underlierder R: Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004;7:155-171.
62. Yee AJ, Kuter DJ: Successful recovery after an overdose of argatroban. Ann Pharmacother 2006;40:336-339.